Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Retinal toxicity after high-dose cisplatin therapy.

G Wilding, R Caruso, T S Lawrence

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |December 1, 1985
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Timing of the definitive procedure and ileostomy closure for total colonic aganglionosis HD: Systematic review.

    Journal of pediatric surgery·2020
    Same author

    Small bowel fed response as measured by wireless motility capsule: Comparative analysis in healthy, gastroparetic, and constipated subjects.

    Neurogastroenterology and motility·2017
    Same author

    Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

    Annals of oncology : official journal of the European Society for Medical Oncology·2017
    Same author

    Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours.

    British journal of cancer·2016
    Same author

    Variable abnormal physiological motility in the proximal upper gastrointestinal tract in gastroparesis.

    Neurogastroenterology and motility·2012
    Same author

    A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer.

    Cancer chemotherapy and pharmacology·2011

    High-dose cisplatin chemotherapy can cause significant vision problems in ovarian cancer patients, including blurred vision and persistent color perception issues. Retinal toxicity, specifically cone dysfunction, was frequently observed, impacting patient quality of life.

    Area of Science:

    • Oncology
    • Ophthalmology
    • Neuroscience

    Background:

    • Ovarian carcinoma is a significant cause of cancer-related mortality in women.
    • Cisplatin is a cornerstone chemotherapy agent used in ovarian cancer treatment.
    • Ophthalmologic toxicity is a potential side effect of platinum-based chemotherapy.

    Purpose of the Study:

    • To evaluate the incidence and characteristics of ophthalmologic toxicity in ovarian carcinoma patients treated with high-dose cisplatin.
    • To investigate the relationship between cisplatin therapy and visual dysfunction, particularly retinal toxicity.

    Main Methods:

    • Retrospective and prospective evaluation of 13 patients with ovarian carcinoma receiving high-dose cisplatin (200 mg/m2).
    • Assessment included clinical examination, electroretinography, and color vision testing.

    Related Experiment Videos

  • Prospective monitoring in three patients before and after cisplatin cycles.

    • Main Results:

    • Ophthalmologic toxicity, including blurred vision and altered color perception, was reported in 62% and 23% of patients, respectively.
    • Retinal toxicity, manifesting as cone dysfunction, was documented in 11 patients (85%) via electroretinography and color vision testing.
    • Prospective data suggested a causal link between cisplatin and retinal abnormalities, with persistent color vision deficits up to 16 months post-therapy.

    Conclusions:

    • High-dose cisplatin therapy is associated with significant ophthalmologic toxicity in ovarian carcinoma patients, primarily affecting retinal function.
    • Cone dysfunction and persistent color vision abnormalities are notable side effects requiring monitoring.
    • While visual acuity may improve after cessation of therapy, long-term visual disturbances can occur.